Anandamide

Anandamide is a lipid of Fatty Acyls (FA) class. Anandamide is associated with abnormalities such as Dehydration. The involved functions are known as Process, Phenomenon, Phosphorylation, Catabolic Process and Gene Expression. Anandamide often locates in Nuchal region, Microglial and Hepatic. The associated genes with Anandamide are SGPL1 gene, SPTLC1 gene, RPSA gene, KDSR gene and SMPD1 gene. The related lipids are Sphingolipids, Lipopolysaccharides, Lysophospholipids, LYSO-PC and lysophosphatidylethanolamine.

Cross Reference

Introduction

To understand associated biological information of Anandamide, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Anandamide?

Anandamide is suspected in Dehydration and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Anandamide

MeSH term MeSH ID Detail
Somatosensory Disorders D020886 1 associated lipids
Orthostatic Intolerance D054971 1 associated lipids
Sleep Disorders, Intrinsic D020919 1 associated lipids
Headache Disorders, Secondary D051271 1 associated lipids
Vascular System Injuries D057772 2 associated lipids
Amnesia, Anterograde D020324 2 associated lipids
Substance-Related Disorders D019966 2 associated lipids
Ocular Hypotension D015814 2 associated lipids
Acute Pain D059787 3 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Schistosomiasis japonica D012554 3 associated lipids
Bulimia D002032 3 associated lipids
Impotence, Vasculogenic D018783 4 associated lipids
Urinary Bladder Diseases D001745 4 associated lipids
Urinary Incontinence D014549 4 associated lipids
Picornaviridae Infections D010850 4 associated lipids
Fibromyalgia D005356 4 associated lipids
Brain Concussion D001924 5 associated lipids
Muscle Spasticity D009128 5 associated lipids
Sleep Deprivation D012892 5 associated lipids
Pregnancy, Ectopic D011271 5 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Brain Damage, Chronic D001925 6 associated lipids
Cholangiocarcinoma D018281 7 associated lipids
Anorexia D000855 8 associated lipids
Morphine Dependence D009021 9 associated lipids
Sleep Apnea, Obstructive D020181 9 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Migraine Disorders D008881 11 associated lipids
Learning Disorders D007859 11 associated lipids
Shock, Septic D012772 11 associated lipids
Overweight D050177 11 associated lipids
Hyperkinesis D006948 11 associated lipids
Hepatitis D006505 11 associated lipids
Hypertension, Portal D006975 12 associated lipids
Multiple Sclerosis D009103 13 associated lipids
Bradycardia D001919 13 associated lipids
Neoplasms D009369 13 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Cardiomyopathy, Dilated D002311 15 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Ventricular Fibrillation D014693 16 associated lipids
Celiac Disease D002446 16 associated lipids
Parkinson Disease, Secondary D010302 17 associated lipids
Pancreatitis, Acute Necrotizing D019283 18 associated lipids
Bronchial Spasm D001986 18 associated lipids
Mycoses D009181 18 associated lipids
Hypothermia D007035 19 associated lipids
Peptic Ulcer D010437 19 associated lipids
Cough D003371 19 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Ataxia D001259 20 associated lipids
Brain Edema D001929 20 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Breast Neoplasms D001943 24 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Hyperemia D006940 25 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Endotoxemia D019446 27 associated lipids
Hyperinsulinism D006946 27 associated lipids
Neuralgia D009437 28 associated lipids
Obesity D009765 29 associated lipids
Catalepsy D002375 30 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Memory Disorders D008569 33 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Fever D005334 35 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Epilepsy D004827 35 associated lipids
Nervous System Diseases D009422 37 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Hypotension D007022 41 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Hyperalgesia D006930 42 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Fatty Liver D005234 48 associated lipids
Nerve Degeneration D009410 53 associated lipids
Pain D010146 64 associated lipids
Reperfusion Injury D015427 65 associated lipids
Neuroblastoma D009447 66 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Melanoma D008545 69 associated lipids
Colitis D003092 69 associated lipids
Stomach Ulcer D013276 75 associated lipids
Alzheimer Disease D000544 76 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Seizures D012640 87 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Insulin Resistance D007333 99 associated lipids
Weight Gain D015430 101 associated lipids
Glioma D005910 112 associated lipids
Hypertension D006973 115 associated lipids
Per page 10 20 50 100 | Total 105

PubChem Associated disorders and diseases

What pathways are associated with Anandamide

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Anandamide?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Anandamide?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Anandamide?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Anandamide?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Anandamide?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Anandamide

Download all related citations
Per page 10 20 50 100 | Total 2222
Authors Title Published Journal PubMed Link
Starowicz K et al. Biochemistry and pharmacology of endovanilloids. 2007 Pharmacol. Ther. pmid:17349697
Burstein SH The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential. 1999 Pharmacol. Ther. pmid:10341359
Izzo AA and Sharkey KA Cannabinoids and the gut: new developments and emerging concepts. 2010 Pharmacol. Ther. pmid:20117132
Porter AC and Felder CC The endocannabinoid nervous system: unique opportunities for therapeutic intervention. 2001 Pharmacol. Ther. pmid:11448725
Woodward DF et al. The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products. 2008 Pharmacol. Ther. pmid:18700152
McFarland MJ and Barker EL Anandamide transport. 2004 Pharmacol. Ther. pmid:15518883
Randall MD et al. Cardiovascular effects of cannabinoids. 2002 Pharmacol. Ther. pmid:12182966
Snider NT et al. Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications. 2010 Pharmacol. Rev. pmid:20133390
Blankman JL and Cravatt BF Chemical probes of endocannabinoid metabolism. 2013 Pharmacol. Rev. pmid:23512546
Mulè F et al. Evidence for a modulatory role of cannabinoids on the excitatory NANC neurotransmission in mouse colon. 2007 Pharmacol. Res. pmid:17574859
Khasabova IA et al. JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy. 2014 Pharmacol. Res. pmid:25304184
Mulè F et al. Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations. 2007 Pharmacol. Res. pmid:17656103
Navarria A et al. The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis. 2014 Pharmacol. Res. pmid:24861565
Kerr DM et al. Pharmacological inhibition of fatty acid amide hydrolase attenuates social behavioural deficits in male rats prenatally exposed to valproic acid. 2016 Pharmacol. Res. pmid:27592249
Yousif MH and Oriowo MA Inhibitory effects of cannabinoid receptor ligands on electrically-evoked responses in rat isolated tracheal ring segments. 1999 Pharmacol. Res. pmid:10527656
Spradley JM et al. Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms. 2010 Pharmacol. Res. pmid:20416378
Guindon J et al. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. 2013 Pharmacol. Res. pmid:23127915
De Petrocellis L et al. N-palmitoyl-vanillamide (palvanil) is a non-pungent analogue of capsaicin with stronger desensitizing capability against the TRPV1 receptor and anti-hyperalgesic activity. 2011 Pharmacol. Res. pmid:21215315
Stefano GB et al. 2-arachidonyl-glycerol stimulates nitric oxide release from human immune and vascular tissues and invertebrate immunocytes by cannabinoid receptor 1. 2000 Pharmacol. Res. pmid:10987990
Malek N et al. The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain. 2016 Pharmacol. Res. pmid:27326920
Fowler CJ and Ghafouri N Does the hydrolysis of 2-arachidonoylglycerol regulate its cellular uptake? 2008 Pharmacol. Res. pmid:18675915
Nicolussi S et al. Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB/c mice. 2014 Pharmacol. Res. pmid:24412246
Maione S et al. Piperazinyl carbamate fatty acid amide hydrolase inhibitors and transient receptor potential channel modulators as "dual-target" analgesics. 2013 Pharmacol. Res. pmid:23911581
Khasabova IA et al. Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain. 2011 Pharmacol. Res. pmid:21440630
Baranowska-Kuczko M et al. Endothelium-dependent mechanisms of the vasodilatory effect of the endocannabinoid, anandamide, in the rat pulmonary artery. 2012 Pharmacol. Res. pmid:22627170
Fowler CJ et al. The endocannabinoid signaling system: pharmacological and therapeutic aspects. 2005 Pharmacol. Biochem. Behav. pmid:15935456
Smith FL et al. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. 1998 Pharmacol. Biochem. Behav. pmid:9610941
Wiley JL Cannabis: discrimination of "internal bliss"? 1999 Pharmacol. Biochem. Behav. pmid:10515300
Romero J et al. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol. 1995 Pharmacol. Biochem. Behav. pmid:7675852
Wiley JL and Burston JJ Chronic Delta9-tetrahydrocannabinol during adolescence increases sensitivity to subsequent cannabinoid effects in delayed nonmatch-to-position in rats. 2010 Pharmacol. Biochem. Behav. pmid:19941884
Herrera-Solís A et al. Acute and subchronic administration of anandamide or oleamide increases REM sleep in rats. 2010 Pharmacol. Biochem. Behav. pmid:20056119
Rawls SM et al. Role of TRPV1 and cannabinoid CB1 receptors in AM 404-evoked hypothermia in rats. 2006 Pharmacol. Biochem. Behav. pmid:16647109
Crawley JN et al. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. 1993 Pharmacol. Biochem. Behav. pmid:7906042
Wiley JL et al. Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys. 1997 Pharmacol. Biochem. Behav. pmid:9408225
Wenger T et al. The effects of prenatally administered endogenous cannabinoid on rat offspring. 1997 Pharmacol. Biochem. Behav. pmid:9300616
Reyes-Cabello C et al. Effects of the anandamide uptake blocker AM404 on food intake depend on feeding status and route of administration. 2012 Pharmacol. Biochem. Behav. pmid:22133635
Tuboly G et al. The antinociceptive interaction of anandamide and adenosine at the spinal level. 2009 Pharmacol. Biochem. Behav. pmid:18760296
Sulcova E et al. Biphasic effects of anandamide. 1998 Pharmacol. Biochem. Behav. pmid:9476980
Sadhasivam S et al. Novel associations between FAAH genetic variants and postoperative central opioid-related adverse effects. 2015 Pharmacogenomics J. pmid:25558980
Laine K et al. Effects of topical anandamide-transport inhibitors, AM404 and olvanil, on intraocular pressure in normotensive rabbits. 2001 Pharm. Res. pmid:11451037
Pate DW et al. Effects of topical alpha-substituted anandamides on intraocular pressure in normotensive rabbits. 1997 Pharm. Res. pmid:9453062
Krishtal O et al. The agonists for nociceptors are ubiquitous, but the modulators are specific: P2X receptors in the sensory neurons are modulated by cannabinoids. 2006 Pflugers Arch. pmid:16741755
Kenessey I et al. Revisiting CB1 receptor as drug target in human melanoma. 2012 Pathol. Oncol. Res. pmid:22447182
Farquhar-Smith WP et al. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. 2002 Pain pmid:12031775
Horvath G et al. The role of TRPV1 receptors in the antinociceptive effect of anandamide at spinal level. 2008 Pain pmid:17533116
Lichtman AH et al. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. 2004 Pain pmid:15157693
Guindon J et al. Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain. 2006 Pain pmid:16480822
Jaggar SI et al. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. 1998 Pain pmid:9696473
Butler RK et al. Endocannabinoid-mediated enhancement of fear-conditioned analgesia in rats: opioid receptor dependency and molecular correlates. 2008 Pain pmid:19004548
Richardson JD et al. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. 1998 Pain pmid:9539680